Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma? (Q38016373)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sagun D Goyal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

Current hematologic malignancy reports

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

179-185

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22669711%20AND%20SRC:MED&resulttype=core&format=json

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

Vinorelbine in the treatment of lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0126-1

Management of Hodgkin lymphoma in relapse after autologous stem cell transplant

21 January 2018

1 reference

12 December 2020

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

1 reference

12 December 2020

Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.

1 reference

12 December 2020

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

1 reference

12 December 2020